Skip to content

Whole-Body Vibration Versus Neuro Muscular Electrical Stimulation on Patients With ICU Acquired Weakness

Effect of Whole-Body Vibration Versus Neuro Muscular Electrical Stimulation on Patients With Intensive Care Acquired Weakness

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07336810
Enrollment
60
Registered
2026-01-13
Start date
2026-01-10
Completion date
2026-04-30
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care (ICU), Intensive Care (ICU) Myopathy, Muscle Weakness | Patient

Keywords

Intensive Care Unit Acquired Weakness, NEURO MUSCULAR ELECTRICAL STIMULATION

Brief summary

Purpose: to investigate the effect of Whole-body vibration versus neuro-muscular electrical stimulation on patients with intensive care-acquired weakness. Methods: Sixty patients with Intensive Care Unit-acquired weakness (ICU AW) from both genders will be recruited and randomly assigned into two groups, Group A and Group B. Group A will include 30 patients who will practice Whole body vibration for two weeks twice daily in addition to their plan of treatment. Group B will include 30 patients who will receive neuromuscular electrical stimulation for two weeks, twice daily, in addition to their plan of treatment. All patients will be evaluated pre- and post-treatment for the MRC score, creatine phosphokinase, and total muscle strength and skeletal muscle thickness

Detailed description

A) Procedure for evaluation: The practical section of the study will be undertaken in 2 weeks (two sessions per day). Measurements will be taken before the start of the training program then after the end of the 2-week training program in the following manner: 1. Manual muscle test (MMT) and medical research council score (MRC): will be used to assess muscle strength. 2. Laboratory investigations for CPK: Blood serum samples will be collected. For each sample, 5 mL of blood will be drawn for laboratory analyses to detect damage in skeletal muscle. 3. Strength Testing with Dynamometry: A Handheld Dynamometer will be used to assess the skeletal muscle strength objectively. 4. Skeletal muscle ultrasonography: will be used to assess the size and thickness of muscles. B) Training procedures: All patients in both groups will receive their plan of treatment in addition to the training program for each group as follows: Group (A) patients in this group will participate in Whole Body Vibration (WBV) training for 2 weeks, two sessions per day (total 14 sessions) in addition to their plan of treatment. Group (B) patients in this group will participate in neuromuscular electrical stimulation (NMES) training for 2 weeks, two sessions per day ( total 14 sessions), in addition to their plan of treatment. C) The statistical analysis will be conducted by using the SPSS statistical package program version 25 for Windows (SPSS, Inc., Chicago, IL). Quantitative descriptive statistics data, including the mean and standard deviation, will be used to describe the data. Multivariate analysis of variance (MANOVA) will be used to compare the tested major dependent variables of interest. A mixed-design 2 x 2 MANOVA test will be used to detect within-group changes and between-group differences. The Bonferroni correction test will be used for pairwise comparison within and between groups of the tested dependent variables, whose P-value will be significant from the MANOVA test. The significance level for all statistical analyses will be set at p\<0.05.

Interventions

DEVICEwhole body VIBRATION Viberation

Whole body vibration will be applied twice daily for two weeks. The patients will be in the supine position during the entire intervention, and no changes in body position will take place to avoid any influence on hemodynamic parameters and vital signs. Following baseline measurements, patients will be mobilized passively for 6 minutes as a warm-up. whole body vibration treatment will be initiated, consisting of a vibration plate device will placed under the patient's feet, with resistance to the end of the bed. The patient's hips and knees will be flexed at about 20°. An elastic strip will provide pressure on the knees, pushing the patient's feet against the vibration device. Whole body vibration sessions took 15 minutes, with 9 minutes of clear vibration time. The vibration frequency will be 25 HZ and the amplitude of 2 mm

Neuromuscular electrical stimulation will be applied twice daily for two weeks. 20 min per muscle group bilaterally on eight different muscle groups (triceps surau (calf muscle), Quadriceps, Hamstring, biceps brachii, triceps brachii, wrist extensors and shoulder abductors). We will never stimulate counteracting muscle groups at the same time. Electrical impulses of 350 μs duration will be applied at a frequency of 50 Hz. Electrical current will be increased until muscle contraction can be visible or palpable, which can be tolerable and does not cause pain or discomfort, and then it will be maintained at this level for the remainder of the session.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* ICU patients who were aged ≥ 18 and \<65. * Sepsis-related Organ Failure assessments (SOFA) score ≥ 9 within the first 72 h after ICU admission. * Patients with no central and peripheral nervous system injury. * Expected to be treated in the ICU for more than 1 week. * Medical Research Council (MRC) sum score of less than 36/60. * Dominant-hand handgrip dynamometry scores of less than 11 kg (interquartile range (IQR) 10-40) in males and less than 7 kg (IQR 0-7.3) in females

Exclusion criteria

* Patients with comorbidities interfering with or compromising the training, like cardiac arrhythmia, pericardial effusion, congestive heart failure, or unstable acute coronary syndrome. * Patients are hemodynamically unstable. * Patients who had a major neurological deficit (upper motor neuron lesion). * Age \< 18 years and more than 65. * Implanted pacemaker or defibrillator. * Pregnancy. * Unhealed fractures or recently attached implants in the body region to be stimulated. * Acute venous thrombosis.

Design outcomes

Primary

MeasureTime frameDescription
Manual muscle test (MMT) and Medical Research Council (MRC)At baseline and post two weeksManual muscle testing will be assessed bilaterally, including tibialis anterior, triceps surae, quadriceps, hamstrings, biceps brachii, triceps brachii, and wrist extensors. These muscles will be assessed in 5 grades of muscle testing, where grade zero means no contraction and grade five means active movement through the full range of motion against full applied resistance against gravity. The MRC scale will be used for early detection of muscle strength, as it has a score ranging from 0 to 60, where \< 48 means significant weakness

Secondary

MeasureTime frameDescription
change of Creatine phosphokinase (CPK-MM)Time Frame: change from baseline CPK-MM level at 2 weeksDescription: The Beckman Unicel DxC800 method will be used for measuring serum CPK-MM
muscle strengthat baseline and post two weeksA handheld dynamometer will be used to measure the muscle strength of the selected muscles by quantifying the force generated when a person pushes or pulls against a stationary device.
muscle thicknessat baseline and post two weeksskeletal muscle ultrasonography will be used to assess muscle thickness

Countries

Egypt

Contacts

STUDY_DIRECTORHeba A. Abd El Ghafar,, A. Professor

Cairo University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026